Skip to main content
. 2013 Feb;15(2):143–155. doi: 10.1593/neo.121712

Figure 4.

Figure 4

(A–E) In vivo response of five different human-derived pancreatic cancers after treatment with vehicle control, lapatinib (L; 65 mg/kg, twice daily), trametinib (0.3 mg/kg, daily), or combination (L + T). (F) Summary of liver metastasis for the same five tumors. (G) Observed liver metastases in mice bearing individual patient-derived tumors. P values are given as follows: *P < .05, **P < .01, ***P < .001.